{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:02:42Z","timestamp":1790100162704,"version":"4.0.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>We evaluated the cost and cost-effectiveness of alternative screening pathways during 2018\u20132022 within Georgia\u2019s hepatitis C elimination program, which started in 2015. We calculated patient-level costs (2022 USD$) of hepatitis C treatment with centralized and decentralized diagnostic testing in hospitals, primary healthcare (PHC), harm reduction providers (HRP), or specialized providers (SP) from reimbursement records including the value of donated direct-acting antivirals (DAAs). We model hepatitis C case-finding, transmission, and progression over a 20-year time horizon to project cost-effectiveness of treatment for each screening pathway in terms of cost per quality adjusted life year (QALY), compared to a willingness-to-pay threshold of $1,337. Unit costs of treatment decreased from $3942\u2013$4247 across screening pathways in 2018 to $300\u2013$338 in 2022, primarily due to reductions in DAA costs. The cascade of care varied by screening pathway, with highest hepatitis C virus (HCV) antibody prevalence and percent linked to viremia testing among HRP and SP, while total number of patients screened was highest in hospitals. While DAA costs decreased, the cost of case finding increased during 2018\u20132022, with the biggest increase in hospital settings mainly due to decreasing yield. The program was not cost-effective with full DAA costs, but excluding DAA costs or using lower 2022 costs make all pathways cost-effective and SP, HRP, and PHC potentially cost-saving. Donated drugs allowed Georgia\u2019s HCV elimination program to be cost-effective, while future programs with generic drug costs are likely to be cost-effective. Reductions in yield from hospital screening suggest that later stages of elimination programs should prioritise targeted pathways.<\/jats:p>","DOI":"10.1371\/journal.pgph.0007122","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:23:44Z","timestamp":1790097824000},"page":"e0007122","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-5738","authenticated-orcid":true,"given":"Josephine G.","family":"Walker","sequence":"first","affiliation":[{"name":"Bristol Medical School, University of Bristol","place":["Bristol, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tskhomelidze Schumacher","sequence":"additional","affiliation":[{"name":"Task Force for Global Health","place":["Tbilisi, Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Shadaker","sequence":"additional","affiliation":[{"name":"US Centers for Disease Control and Prevention","place":["Atlanta, Georgia, United States of America"],"department":["Division of Viral Hepatitis"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Gabunia","sequence":"additional","affiliation":[{"name":"Ministry of Internally Displaced Persons from Occupied Territories, Health, Labour and Social Affairs","place":["Tbilisi, Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-0338","authenticated-orcid":true,"given":"Rania A.","family":"Tohme","sequence":"additional","affiliation":[{"name":"US Centers for Disease Control and Prevention","place":["Atlanta, Georgia, United States of America"],"department":["Division of Viral Hepatitis"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akaki","family":"Abutidze","sequence":"additional","affiliation":[{"name":"AIDS & Clinical Immunology Research Center","place":["Tbilisi, Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-1908","authenticated-orcid":true,"given":"Vladimer","family":"Getia","sequence":"additional","affiliation":[{"name":"National Center for Disease Control and Public Health","place":["Tbilisi, Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"Bristol Medical School, University of Bristol","place":["Bristol, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"pgph.0007122.ref001","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination","volume":"19","author":"LM Hagan","year":"2019","journal-title":"BMC Public Health"},{"key":"pgph.0007122.ref002","volume-title":"Georgia Hepatitis Elimination Program Progress Report 2020-2021","author":"Ministry of IDPs from the occupied territories, labour, health, and social affairs of Georgia, Centers for Disease Control and Prevention, National Center for Disease Control and Public Health","year":"2022"},{"key":"pgph.0007122.ref003","volume-title":"Centers for Disease Control and Prevention. Strategic Plan for the Elimination of Hepatitis C virus in Georgia, 2016-2020","author":"Ministry of Labour, Health, and Social Affairs, National Centre for Disease Control and Public Health","year":"2016"},{"issue":"30","key":"pgph.0007122.ref004","doi-asserted-by":"crossref","first-page":"660","DOI":"10.15585\/mmwr.mm7330a1","article-title":"Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024","volume":"73","author":"RA Tohme","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pgph.0007122.ref005","unstructured":"World Health Organization. Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. 2024. https:\/\/www.who.int\/publications-detail-redirect\/9789240053779"},{"key":"pgph.0007122.ref006","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiad064","article-title":"Nationwide hepatitis C serosurvey and progress towards hepatitis C virus elimination in the country of Georgia, 2021","volume":"228","author":"A Gamkrelidze","year":"2023","journal-title":"J Infect Dis"},{"issue":"30","key":"pgph.0007122.ref007","doi-asserted-by":"crossref","first-page":"2200952","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200952","article-title":"Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015","volume":"28","author":"JG Walker","year":"2023","journal-title":"Euro Surveill"},{"issue":"3","key":"pgph.0007122.ref008","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/liv.15431","article-title":"Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017","volume":"43","author":"I Tskhomelidze","year":"2023","journal-title":"Liver Int"},{"issue":"6","key":"pgph.0007122.ref009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"J Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"2","key":"pgph.0007122.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(19)30483-8","article-title":"Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study","volume":"8","author":"JG Walker","year":"2020","journal-title":"Lancet Glob Health"},{"key":"pgph.0007122.ref011","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/ 2024."},{"issue":"3","key":"pgph.0007122.ref012","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"CAKY Chong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"pgph.0007122.ref013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","article-title":"A path to eradication of hepatitis C in low- and middle-income countries","volume":"119","author":"CS Graham","year":"2015","journal-title":"Antiviral Res"},{"key":"pgph.0007122.ref014","volume-title":"Global health sector strategy on viral hepatitis 2016-2021: Towards ending viral hepatitis","author":"World Health Organization","year":"2016"},{"key":"pgph.0007122.ref015","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.jval.2022.05.010","article-title":"Another step toward hepatitis C elimination: An economic evaluation of an Irish national birth cohort testing program","volume":"25","author":"PG Carty","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"pgph.0007122.ref016","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/liv.14458","article-title":"The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation","volume":"40","author":"AB Mendlowitz","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"pgph.0007122.ref017","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jvh.13238","article-title":"Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain","volume":"27","author":"J Crespo","year":"2020","journal-title":"J Viral Hepat"},{"issue":"7","key":"pgph.0007122.ref018","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/liv.14408","article-title":"Optimization of hepatitis C virus screening strategies by birth cohort in Italy","volume":"40","author":"LA Kondili","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"pgph.0007122.ref019","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1186\/s12879-019-4524-z","article-title":"Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies","volume":"19","author":"C Krauth","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pgph.0007122.ref020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/liv.13930","article-title":"Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population","volume":"39","author":"K-A Kim","year":"2019","journal-title":"Liver Int"},{"key":"pgph.0007122.ref021","doi-asserted-by":"crossref","first-page":"101176","DOI":"10.1016\/j.lanepe.2024.101176","article-title":"Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study","volume":"49","author":"Z Ward","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"pgph.0007122.ref022","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2055-6640(20)30031-5","article-title":"Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving","volume":"5","author":"S Popping","year":"2019","journal-title":"J Virus Erad"},{"issue":"1","key":"pgph.0007122.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245288","article-title":"Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China","volume":"16","author":"A Heffernan","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"pgph.0007122.ref024","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s40273-021-01064-z","article-title":"Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment","volume":"39","author":"B Asker","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"pgph.0007122.ref025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-066770","article-title":"Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison","volume":"13","author":"JB Babigumira","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"pgph.0007122.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238035","article-title":"Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa","volume":"15","author":"L Duchesne","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"pgph.0007122.ref027","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/liv.15584","article-title":"Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost-effectiveness model","volume":"43","author":"S Ezzat","year":"2023","journal-title":"Liver Int"},{"key":"pgph.0007122.ref028","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11895","article-title":"Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis","volume":"9","author":"M Sadeghimehr","year":"2021","journal-title":"PeerJ"},{"issue":"1","key":"pgph.0007122.ref029","doi-asserted-by":"crossref","first-page":"21382","DOI":"10.1038\/s41598-021-00362-y","article-title":"Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator","volume":"11","author":"M Adee","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"pgph.0007122.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001667","article-title":"Cost-effectiveness of Hepatitis C virus self-testing in four settings","volume":"3","author":"JG Walker","year":"2023","journal-title":"PLOS Glob Public Health"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0007122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:23:50Z","timestamp":1790097830000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0007122"}},"subtitle":[],"editor":[{"given":"Julia","family":"Robinson","sequence":"first","affiliation":[{"name":"PLOS: Public Library of Science","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0007122","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}